Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery remains the only treatment offering an advantage in terms of overall survival (5-year survival range, 15-25%), but unfortunately only 10-20% of patients present resectable disease at the time of diagnosis. He...
Gespeichert in:
| Veröffentlicht in: | Oncology reports 2010-05, Vol.23 (5), p.1183-1192 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1192 |
|---|---|
| container_issue | 5 |
| container_start_page | 1183 |
| container_title | Oncology reports |
| container_volume | 23 |
| creator | DI MARCO, Maria Cristina DI CICILIA, Roberto MACCHINI, Marina NOBILI, Elisabetta VECCHIARELLI, Silvia BRANDI, Giovanni BIASCO, Guido |
| description | Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery remains the only treatment offering an advantage in terms of overall survival (5-year survival range, 15-25%), but unfortunately only 10-20% of patients present resectable disease at the time of diagnosis. Hence chemotherapy, possibly combined with radiation therapy, remains the only treatment option aimed at palliation of symptoms and ensuring a better quality of life. Notwithstanding the efforts to find more effective therapies for the treatment of pancreatic cancer, significant results have not yet been achieved. Increasing interest has focused on integrated treatments, i.e. chemotherapy combined with targeted therapies, and a better selection of patients. This study examines the principal clinical trials that will help give clinicians an overview of the progress made in the systemic therapy for advanced pancreatic cancer patients in recent years. |
| doi_str_mv | 10.3892/or_00000749 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733860499</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733860499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-eeb2dda866330c3f0f62c190c4ea40c59e38f373d2b0c7a4dd5f93007009bf923</originalsourceid><addsrcrecordid>eNpNkM1Lw0AQxRdRrFZP3iUXUZHoZCdNsl5Eih-FiiAKvYXN7kRXkrTubhX_e7e2fsxl3sBvHjOPsb0ETrEQ_GxqS1hUnoo1tpXkIol5isl60MCTGHEw6bFt514BeA6Z2GQ9DpjzgostNrkjL52X3qhoJjtl6VuqIMmeRyMXPVOrjJeV6Shy3jRN5F8oqsj5MMpOS6sjv1hrqfMX0dEDvRv6ON5hG7VsHO2uep89XV89Dm_j8f3NaHg5jlXKEx8TVVxrWWQZIiisoc64SgSolGQKaiAIixpz1LwClctU60EtMDwLIKpacOyzw6XvzE7f5uGqsjVOUdPIjqZzV-aIRQapEIE8WZLKTp2zVJcza1ppP8sEykWS5b8kA72_8p1XLelf9ie6ABysAOmUbGobIjPuj-M5As8AvwBqents</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733860499</pqid></control><display><type>article</type><title>Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>DI MARCO, Maria Cristina ; DI CICILIA, Roberto ; MACCHINI, Marina ; NOBILI, Elisabetta ; VECCHIARELLI, Silvia ; BRANDI, Giovanni ; BIASCO, Guido</creator><creatorcontrib>DI MARCO, Maria Cristina ; DI CICILIA, Roberto ; MACCHINI, Marina ; NOBILI, Elisabetta ; VECCHIARELLI, Silvia ; BRANDI, Giovanni ; BIASCO, Guido</creatorcontrib><description>Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery remains the only treatment offering an advantage in terms of overall survival (5-year survival range, 15-25%), but unfortunately only 10-20% of patients present resectable disease at the time of diagnosis. Hence chemotherapy, possibly combined with radiation therapy, remains the only treatment option aimed at palliation of symptoms and ensuring a better quality of life. Notwithstanding the efforts to find more effective therapies for the treatment of pancreatic cancer, significant results have not yet been achieved. Increasing interest has focused on integrated treatments, i.e. chemotherapy combined with targeted therapies, and a better selection of patients. This study examines the principal clinical trials that will help give clinicians an overview of the progress made in the systemic therapy for advanced pancreatic cancer patients in recent years.</description><identifier>ISSN: 1021-335X</identifier><identifier>EISSN: 1791-2431</identifier><identifier>DOI: 10.3892/or_00000749</identifier><identifier>PMID: 20372829</identifier><language>eng</language><publisher>Athens: Spandidos</publisher><subject><![CDATA[Angiogenesis Inhibitors - administration & dosage ; Antimetabolites, Antineoplastic - administration & dosage ; Antimetabolites, Antineoplastic - adverse effects ; Antimetabolites, Antineoplastic - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carcinoma, Pancreatic Ductal - drug therapy ; Carcinoma, Pancreatic Ductal - metabolism ; Carcinoma, Pancreatic Ductal - secondary ; Chemotherapy, Adjuvant ; Clinical Trials as Topic ; Deoxycytidine - administration & dosage ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Evidence-Based Medicine ; Fluorouracil - administration & dosage ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Medical sciences ; Palliative Care ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - metabolism ; Pancreatic Neoplasms - pathology ; Protein Kinase Inhibitors - administration & dosage ; Radiotherapy, Adjuvant ; Signal Transduction - drug effects ; Treatment Outcome ; Tumors ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vascular Endothelial Growth Factor A - metabolism]]></subject><ispartof>Oncology reports, 2010-05, Vol.23 (5), p.1183-1192</ispartof><rights>2015 INIST-CNRS</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-eeb2dda866330c3f0f62c190c4ea40c59e38f373d2b0c7a4dd5f93007009bf923</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22730260$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20372829$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DI MARCO, Maria Cristina</creatorcontrib><creatorcontrib>DI CICILIA, Roberto</creatorcontrib><creatorcontrib>MACCHINI, Marina</creatorcontrib><creatorcontrib>NOBILI, Elisabetta</creatorcontrib><creatorcontrib>VECCHIARELLI, Silvia</creatorcontrib><creatorcontrib>BRANDI, Giovanni</creatorcontrib><creatorcontrib>BIASCO, Guido</creatorcontrib><title>Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)</title><title>Oncology reports</title><addtitle>Oncol Rep</addtitle><description>Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery remains the only treatment offering an advantage in terms of overall survival (5-year survival range, 15-25%), but unfortunately only 10-20% of patients present resectable disease at the time of diagnosis. Hence chemotherapy, possibly combined with radiation therapy, remains the only treatment option aimed at palliation of symptoms and ensuring a better quality of life. Notwithstanding the efforts to find more effective therapies for the treatment of pancreatic cancer, significant results have not yet been achieved. Increasing interest has focused on integrated treatments, i.e. chemotherapy combined with targeted therapies, and a better selection of patients. This study examines the principal clinical trials that will help give clinicians an overview of the progress made in the systemic therapy for advanced pancreatic cancer patients in recent years.</description><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Antimetabolites, Antineoplastic - administration & dosage</subject><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Pancreatic Ductal - drug therapy</subject><subject>Carcinoma, Pancreatic Ductal - metabolism</subject><subject>Carcinoma, Pancreatic Ductal - secondary</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical Trials as Topic</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - adverse effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Evidence-Based Medicine</subject><subject>Fluorouracil - administration & dosage</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Medical sciences</subject><subject>Palliative Care</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Radiotherapy, Adjuvant</subject><subject>Signal Transduction - drug effects</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><issn>1021-335X</issn><issn>1791-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkM1Lw0AQxRdRrFZP3iUXUZHoZCdNsl5Eih-FiiAKvYXN7kRXkrTubhX_e7e2fsxl3sBvHjOPsb0ETrEQ_GxqS1hUnoo1tpXkIol5isl60MCTGHEw6bFt514BeA6Z2GQ9DpjzgostNrkjL52X3qhoJjtl6VuqIMmeRyMXPVOrjJeV6Shy3jRN5F8oqsj5MMpOS6sjv1hrqfMX0dEDvRv6ON5hG7VsHO2uep89XV89Dm_j8f3NaHg5jlXKEx8TVVxrWWQZIiisoc64SgSolGQKaiAIixpz1LwClctU60EtMDwLIKpacOyzw6XvzE7f5uGqsjVOUdPIjqZzV-aIRQapEIE8WZLKTp2zVJcza1ppP8sEykWS5b8kA72_8p1XLelf9ie6ABysAOmUbGobIjPuj-M5As8AvwBqents</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>DI MARCO, Maria Cristina</creator><creator>DI CICILIA, Roberto</creator><creator>MACCHINI, Marina</creator><creator>NOBILI, Elisabetta</creator><creator>VECCHIARELLI, Silvia</creator><creator>BRANDI, Giovanni</creator><creator>BIASCO, Guido</creator><general>Spandidos</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100501</creationdate><title>Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)</title><author>DI MARCO, Maria Cristina ; DI CICILIA, Roberto ; MACCHINI, Marina ; NOBILI, Elisabetta ; VECCHIARELLI, Silvia ; BRANDI, Giovanni ; BIASCO, Guido</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-eeb2dda866330c3f0f62c190c4ea40c59e38f373d2b0c7a4dd5f93007009bf923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Antimetabolites, Antineoplastic - administration & dosage</topic><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Pancreatic Ductal - drug therapy</topic><topic>Carcinoma, Pancreatic Ductal - metabolism</topic><topic>Carcinoma, Pancreatic Ductal - secondary</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical Trials as Topic</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - adverse effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Evidence-Based Medicine</topic><topic>Fluorouracil - administration & dosage</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Medical sciences</topic><topic>Palliative Care</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Radiotherapy, Adjuvant</topic><topic>Signal Transduction - drug effects</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><toplevel>online_resources</toplevel><creatorcontrib>DI MARCO, Maria Cristina</creatorcontrib><creatorcontrib>DI CICILIA, Roberto</creatorcontrib><creatorcontrib>MACCHINI, Marina</creatorcontrib><creatorcontrib>NOBILI, Elisabetta</creatorcontrib><creatorcontrib>VECCHIARELLI, Silvia</creatorcontrib><creatorcontrib>BRANDI, Giovanni</creatorcontrib><creatorcontrib>BIASCO, Guido</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DI MARCO, Maria Cristina</au><au>DI CICILIA, Roberto</au><au>MACCHINI, Marina</au><au>NOBILI, Elisabetta</au><au>VECCHIARELLI, Silvia</au><au>BRANDI, Giovanni</au><au>BIASCO, Guido</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)</atitle><jtitle>Oncology reports</jtitle><addtitle>Oncol Rep</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>23</volume><issue>5</issue><spage>1183</spage><epage>1192</epage><pages>1183-1192</pages><issn>1021-335X</issn><eissn>1791-2431</eissn><abstract>Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery remains the only treatment offering an advantage in terms of overall survival (5-year survival range, 15-25%), but unfortunately only 10-20% of patients present resectable disease at the time of diagnosis. Hence chemotherapy, possibly combined with radiation therapy, remains the only treatment option aimed at palliation of symptoms and ensuring a better quality of life. Notwithstanding the efforts to find more effective therapies for the treatment of pancreatic cancer, significant results have not yet been achieved. Increasing interest has focused on integrated treatments, i.e. chemotherapy combined with targeted therapies, and a better selection of patients. This study examines the principal clinical trials that will help give clinicians an overview of the progress made in the systemic therapy for advanced pancreatic cancer patients in recent years.</abstract><cop>Athens</cop><pub>Spandidos</pub><pmid>20372829</pmid><doi>10.3892/or_00000749</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1021-335X |
| ispartof | Oncology reports, 2010-05, Vol.23 (5), p.1183-1192 |
| issn | 1021-335X 1791-2431 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733860499 |
| source | MEDLINE; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Angiogenesis Inhibitors - administration & dosage Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - secondary Chemotherapy, Adjuvant Clinical Trials as Topic Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Evidence-Based Medicine Fluorouracil - administration & dosage Gastroenterology. Liver. Pancreas. Abdomen Humans Liver. Biliary tract. Portal circulation. Exocrine pancreas Medical sciences Palliative Care Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Protein Kinase Inhibitors - administration & dosage Radiotherapy, Adjuvant Signal Transduction - drug effects Treatment Outcome Tumors Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - metabolism |
| title | Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T17%3A05%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metastatic%20pancreatic%20cancer:%20Is%20gemcitabine%20still%20the%20best%20standard%20treatment?%20(Review)&rft.jtitle=Oncology%20reports&rft.au=DI%20MARCO,%20Maria%20Cristina&rft.date=2010-05-01&rft.volume=23&rft.issue=5&rft.spage=1183&rft.epage=1192&rft.pages=1183-1192&rft.issn=1021-335X&rft.eissn=1791-2431&rft_id=info:doi/10.3892/or_00000749&rft_dat=%3Cproquest_cross%3E733860499%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733860499&rft_id=info:pmid/20372829&rfr_iscdi=true |